Show simple item record

dc.contributor.authorRodríguez-Osorio, Iria
dc.contributor.authorCid-Silva, Purificación
dc.contributor.authorMorano, Luis
dc.contributor.authorCastro-Iglesias, Ángeles
dc.contributor.authorSuárez, Marta
dc.contributor.authorDelgado, Manuel
dc.contributor.authorMargusino-Framiñán, Luis
dc.contributor.authorMeijide, Héctor
dc.contributor.authorPernas, Berta
dc.contributor.authorTabernilla, Andrés
dc.contributor.authorPedreira, José D.
dc.contributor.authorMena, Álvaro
dc.contributor.authorPoveda, Eva
dc.date.accessioned2017-04-17T10:53:03Z
dc.date.issued2017-01-18
dc.identifier.citation61es_ES
dc.identifier.issn1386-6532
dc.identifier.issn1873-5967
dc.identifier.urihttp://hdl.handle.net/2183/18395
dc.descriptionShort communicationes_ES
dc.description.abstract[Abstract] Background. New direct-acting antivirals agents (DAAs) are very safe and well tolerated. Objectives. The purpose of this study is to analyse the efficacy and safety of DAAs in elderly patients, who have co-morbidities and are on chronic medications. Study design. All HCV-infected patients over 65 years old in clinical follow-up at two Hospitals in Spain who initiated anti-HCV therapy were included (August 2012–October 2015). Results. A total of 120 HCV mono-infected patients were recorded. Mean age of patients was 72.6 ± 7.4 years. There were 53.3% women and GT1b was the most frequent (83.3%); 64.2% had cirrhosis and 42.5% were treatment experienced. Ombitasvir + Paritaprevir/r ± Dasabuvir ± Ribavirin (RBV) and sofosbuvir/ledipasvir ± RBV were the most frequently used regimens. Weight-adjusted dosing of RBV was included in 61.7% and 43.6% of them required a dose reduction. Most of the patients (86.7%) had concomitant chronic medication and in 35.8% adjustment was necessary. Adverse events (AE) were seen in 65% of the patients; more frequent when a protease inhibitor (PI) was being used. The sustained virological response (SVR12) per ITT was 88.3%. Only 3 patients discontinued treatment and 2 patients died. Conclusions. High rates of SVR12 (88.3%) were observed among elderly patients with DAAs-based regimens. The presence of AE was frequent (65%). The majority of these patients (86.7%) had concomitant medication that required adjustment in 1/3 of them. These findings highlight the high rates of response to DAAs in the elderly HCV-population. However, special caution must be taken when using RBV and a PI.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CPII14/00014es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI10/02166es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; PI13/02266es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; CM15/00233es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.relation.urihttp://doi.org/10.1016/j.jcv.2017.01.003es_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 Españaes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.titleReal life experience with direct-acting antivirals agents against hepatitis C infection in elderly patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/embargoedAccesses_ES
dc.date.embargoEndDate2018-01-18es_ES
dc.date.embargoLift2018-01-18
UDC.journalTitleJournal of Clinical Virologyes_ES
UDC.volume88es_ES
UDC.endPage58es_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record